Return to content in this issue

A pilot experience using a one-bag intravenous rapid desensitization protocol for chemotherapeutics and biologics in a cohort of patients with access to a delabeling pathway

Vázquez-Revuelta P^1,2,3, Lleonart-Bellfill R^1,2,3, Molina-Mata K^1,4, Muñoz-Sánchez Pharm C^1,5, Rey-Salido Pharm M^1,5, Madrigal-Burgaleta R<sup>1,6

1</sup>Drug Desensitisation Centre, Catalan Institute of Oncology (Institut Català d’Oncologia – ICO), Barcelona, Spain
²Allergy Service, Hospital Universitari de Bellvitge, Barcelona, Spain
³Institut d’Investigació Biomèdica de Bellvitge ‐ IDIBELL, Barcelona, Spain
⁴Medical Oncology Service, Catalan Institute of Oncology (Institut Català d’Oncologia – ICO), Barcelona, Spain
⁵Pharmacy Service, Catalan Institute of Oncology (Institut Català d’Oncologia – ICO), Barcelona, Spain
⁶Allergy & Severe Asthma Service, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK

J Investig Allergol Clin Immunol 2023; Vol. 33(4)
doi: 10.18176/jiaci.0860

• Abstract
• Supplemental Materials

Key words: Drug allergy, Delabeling, Drug challenge, Desensitization, Personalized medicine

	Title	Type	Size
	doi10.18176_jiaci.0860_supplemental-materials-figure.pdf	pdf	317.23 Kb
	doi10.18176_jiaci.0860_supplemental-materials-table.pdf	pdf	232.73 Kb